NO894946L - Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff. - Google Patents
Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff.Info
- Publication number
- NO894946L NO894946L NO89894946A NO894946A NO894946L NO 894946 L NO894946 L NO 894946L NO 89894946 A NO89894946 A NO 89894946A NO 894946 A NO894946 A NO 894946A NO 894946 L NO894946 L NO 894946L
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal antibody
- reducing tissue
- bottle
- procedure
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/061,336 US4840793A (en) | 1987-06-11 | 1987-06-11 | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
US07/165,025 US4935234A (en) | 1987-06-11 | 1988-03-07 | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
PCT/US1988/001928 WO1988009672A1 (en) | 1987-06-11 | 1988-06-03 | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
NO894946D0 NO894946D0 (no) | 1989-12-08 |
NO894946L true NO894946L (no) | 1990-01-23 |
Family
ID=26740960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO89894946A NO894946L (no) | 1987-06-11 | 1989-12-08 | Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff. |
Country Status (12)
Country | Link |
---|---|
US (1) | US4935234A (ja) |
EP (1) | EP0371036B1 (ja) |
JP (1) | JPH02503796A (ja) |
CN (1) | CN1034055C (ja) |
AT (1) | ATE126703T1 (ja) |
AU (1) | AU621304B2 (ja) |
BR (1) | BR8807559A (ja) |
CA (1) | CA1317880C (ja) |
DE (1) | DE3854351T2 (ja) |
DK (1) | DK620089A (ja) |
NO (1) | NO894946L (ja) |
WO (1) | WO1988009672A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019648A (en) * | 1987-07-06 | 1991-05-28 | Dana-Farber Cancer Institute | Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein |
US5395929A (en) * | 1987-12-15 | 1995-03-07 | Dana Farber Cancer Institute | Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor |
US4986979A (en) * | 1989-03-14 | 1991-01-22 | Neorx Corporation | Imaging tissue sites of inflammation |
ZA903223B (en) * | 1989-04-28 | 1991-02-27 | Baylor College Medicine | Dissemination of hiv-1 infected cells |
WO1992003473A1 (en) * | 1990-08-27 | 1992-03-05 | Cetus Corporation | Cd18 peptide medicaments for the treatment of disease |
WO1992006697A1 (en) * | 1990-10-23 | 1992-04-30 | Repligen Corporation | Anti-inflammatory composition |
JPH06505969A (ja) * | 1991-01-11 | 1994-07-07 | レプリジェン コーポレーション | 炎症性損傷防止方法 |
US5322699A (en) * | 1991-02-04 | 1994-06-21 | The Rockefeller University | Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1) |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5708141A (en) * | 1992-05-11 | 1998-01-13 | Corvas International, Inc. | Neutrophil inhibitors |
WO1993024614A1 (en) * | 1992-05-22 | 1993-12-09 | The Research And Development Institute, Inc. | Antibodies with specificity for multiple adhesion molecules |
EP0670734A4 (en) * | 1992-10-09 | 1998-01-14 | Blood Res Center | SUB-POPULATION OF Mac-1 MOLECULES (CD11B / CD 18) THAT INDUCE NEUTROPHILIC ADHESION TO ICAM-1 AND FIBRINOGEN. |
GB9312315D0 (en) * | 1993-06-15 | 1993-07-28 | Poston Robin | Leukocyte adhesion assay |
US5681699A (en) * | 1994-02-11 | 1997-10-28 | Cedars-Sinai Medical Center | Methods of diagnosing ulcerative colitis and Crohn's disease |
US6884590B1 (en) | 1994-02-11 | 2005-04-26 | Cedars-Sinai Medical Center | Methods of screening for ulcerative colitis and crohn's disease |
US5656441A (en) * | 1994-04-19 | 1997-08-12 | Trustees Of Boston University | Methods for determining cellular adhesion |
US5797870A (en) * | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
US6001356A (en) * | 1995-09-29 | 1999-12-14 | Rush-Presbyterian-St. Luke's Medical Center | Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies |
US20020081294A1 (en) | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
AU4000500A (en) * | 1999-02-17 | 2000-09-04 | Genentech Inc. | Co-administration of a thrombolytic and an anti-cd18 antibody |
US6663863B2 (en) | 2000-03-17 | 2003-12-16 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
AU2003217747A1 (en) * | 2002-02-26 | 2003-09-09 | North Shore-Long Island Jewish Research Insitute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
EP1819827B1 (en) * | 2004-12-08 | 2010-08-11 | Cedars-Sinai Medical Center | Methods for diagnosis of crohn's disease |
CN102793972A (zh) | 2004-12-27 | 2012-11-28 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病 |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
US20100021917A1 (en) * | 2007-02-14 | 2010-01-28 | Cedars-Sinai Medical Center | Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease |
US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
US20100015156A1 (en) * | 2007-03-06 | 2010-01-21 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease in children |
WO2008116150A2 (en) | 2007-03-21 | 2008-09-25 | Cedars-Sinai Medical Center | Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease |
WO2008134569A2 (en) * | 2007-04-26 | 2008-11-06 | Cedars-Sinai Medical Center | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population |
US20100144903A1 (en) * | 2007-05-04 | 2010-06-10 | Cedars-Sinai Medical Center | Methods of diagnosis and treatment of crohn's disease |
US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
US20110177969A1 (en) * | 2008-10-01 | 2011-07-21 | Cedars-Sinai Medical Center | The role of il17rd and the il23-1l17 pathway in crohn's disease |
US20110189685A1 (en) * | 2008-10-22 | 2011-08-04 | Cedars-Sinai Medical Center | Methods of using jak3 genetic variants to diagnose and predict crohn's disease |
ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
EP2440284B1 (en) | 2009-06-09 | 2018-09-12 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
BR112015024752A2 (pt) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
EP3405107B1 (en) | 2016-01-20 | 2023-04-12 | Setpoint Medical Corporation | Control of vagal stimulation |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
WO2021236977A1 (en) | 2020-05-21 | 2021-11-25 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4840793A (en) * | 1987-06-11 | 1989-06-20 | Dana-Farber Cancer Institute | Method of reducing tissue damage at an inflammatory site using a monoclonal antibody |
-
1988
- 1988-03-07 US US07/165,025 patent/US4935234A/en not_active Expired - Lifetime
- 1988-06-03 DE DE3854351T patent/DE3854351T2/de not_active Expired - Fee Related
- 1988-06-03 EP EP88905555A patent/EP0371036B1/en not_active Expired - Lifetime
- 1988-06-03 BR BR888807559A patent/BR8807559A/pt not_active Application Discontinuation
- 1988-06-03 JP JP63505211A patent/JPH02503796A/ja active Pending
- 1988-06-03 WO PCT/US1988/001928 patent/WO1988009672A1/en active IP Right Grant
- 1988-06-03 AT AT88905555T patent/ATE126703T1/de not_active IP Right Cessation
- 1988-06-03 AU AU19463/88A patent/AU621304B2/en not_active Ceased
- 1988-06-10 CN CN88103476A patent/CN1034055C/zh not_active Expired - Fee Related
- 1988-06-10 CA CA000569247A patent/CA1317880C/en not_active Expired - Fee Related
-
1989
- 1989-12-08 DK DK620089A patent/DK620089A/da not_active Application Discontinuation
- 1989-12-08 NO NO89894946A patent/NO894946L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0371036B1 (en) | 1995-08-23 |
CN1033242A (zh) | 1989-06-07 |
DK620089A (da) | 1990-02-07 |
DE3854351T2 (de) | 1996-03-21 |
JPH02503796A (ja) | 1990-11-08 |
DK620089D0 (da) | 1989-12-08 |
WO1988009672A1 (en) | 1988-12-15 |
AU621304B2 (en) | 1992-03-12 |
CA1317880C (en) | 1993-05-18 |
EP0371036A4 (en) | 1990-06-27 |
NO894946D0 (no) | 1989-12-08 |
BR8807559A (pt) | 1990-05-22 |
CN1034055C (zh) | 1997-02-19 |
ATE126703T1 (de) | 1995-09-15 |
AU1946388A (en) | 1989-01-04 |
DE3854351D1 (de) | 1995-09-28 |
EP0371036A1 (en) | 1990-06-06 |
US4935234A (en) | 1990-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO894946L (no) | Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff. | |
NO982062L (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
NL186846C (nl) | Waterig preparaat voor de behandeling van vezelig materiaal, en werkwijze voor het behandelen van vezelig materiaal. | |
ATA29495A (de) | Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a | |
EP0313378A3 (en) | Methods and compositions for transient elimination of humoral immune antibodies | |
DE69027220D1 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
ATE104852T1 (de) | Verwendung von bicyclischen imidazol-verbindungen zur behandlung von hyperaldosteronismus. | |
NO894222D0 (no) | Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder. | |
Mebs et al. | Snake venom hemorrhagins: neutralization by commercial antivenoms | |
Paronetto et al. | Immunologic observations on homografts: I. The canine liver | |
Ueda et al. | Experimental gold nephropathy in guinea pigs: detection of autoantibodies to renal tubular antigens | |
KR970701063A (ko) | 안티트롬빈제 용도로써 피브린-특이적 항체(fibrin-specific antibody for use as an antithrombotic agent) | |
ATE55059T1 (de) | Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen. | |
NL187299B (nl) | Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten. | |
Van Amerongen et al. | Immunofluorescent localization and extractability of fibronectin in human dental pulp | |
DE60045638D1 (de) | Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen | |
ATE167628T1 (de) | Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion | |
NL7902450A (nl) | Farmaceutisch preparaat met anti-complementaire wer- king, werkwijze voor de bereiding daarvan alsmede werk- wijze voor het behandelen van nephritis. | |
JPS58501543A (ja) | ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良 | |
PETERSSON | Induction of Histamine Release and Desensitization in Human Leukocytes: IgG‐Mediated Histamine Release | |
IE811612L (en) | Thiazoles | |
Connell et al. | Allotype suppression in rabbits: the requirement for CH3 domain of anti-allotype antibody | |
Yamaguchi et al. | Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy | |
Garcia-Leme | Role of lymphocytes in non-immune experimental inflammation | |
Koyama et al. | Platelet involvement in the nephritis of acute serum sickness in rabbits: protection by dipyridamole and FUT-175. |